First, the correct name is retatrutide
Searches often use spellings such as “rettrutide” or “retatrutude.” The investigational medicine developed by Eli Lilly is retatrutide (LY3437943). It activates three hormone-receptor pathways: GIP, GLP-1 and glucagon. That triple action distinguishes it from semaglutide, which acts at GLP-1 receptors, and tirzepatide, which acts at GIP and GLP-1 receptors.
Why the results have attracted attention
In a peer-reviewed phase 2 trial of 338 adults, average weight change at 48 weeks ranged from −8.7% at the lowest studied dose to −24.2% at the highest, compared with −2.1% for placebo. Gastrointestinal adverse events were common and discontinuation due to adverse events occurred in some treatment groups. Phase 2 results are designed to help define dose, benefit and risk; they are not sufficient by themselves for routine clinical use.
On 21 May 2026, Lilly announced topline results from the phase 3 TRIUMPH-1 trial. The company reported an average 28.3% weight reduction at 80 weeks in the highest-dose group and stated that 45.3% achieved at least 30% weight reduction. These results are important, but at the time of this review they were manufacturer-reported topline results. Full peer-reviewed publication and regulatory assessment remain important.
What we still need to know
- the complete phase 3 safety and discontinuation data after peer review;
- how regulators assess benefit, dosing, contraindications and monitoring;
- long-term maintenance, weight regain after stopping and real-world adherence;
- effects on nutrition, lean mass and tolerability across different populations;
- authorized manufacturing, cold-chain supply and future status in Pakistan;
- how its benefits and harms compare in practice with established treatments and metabolic surgery.
Why “retatrutide for sale” is a warning sign
The U.S. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under U.S. federal law. The agency has warned companies marketing unapproved retatrutide. A vial labelled “retatrutide” cannot be authenticated by appearance, and “research use” wording does not make a product suitable for human injection.
Patients should not purchase retatrutide through social media, messaging apps, gyms, unverified clinics or websites. There is no safe dose for a product whose identity, strength, sterility and storage are unknown.
How it differs from medicines used now
| Medicine | Receptor action | Clinical status at this review |
|---|---|---|
| Semaglutide | GLP-1 | Approved products exist for defined indications; product and Pakistani status must be verified |
| Tirzepatide | GIP + GLP-1 | Approved products exist in some jurisdictions; product and Pakistani status must be verified |
| Retatrutide | GIP + GLP-1 + glucagon | Investigational; not FDA-approved and not offered by this clinic |
Frequently asked questions
Is retatrutide the same as Mounjaro?
No. Mounjaro contains tirzepatide. Retatrutide is a different investigational triple-receptor agonist.
Can Dr. Fowad prescribe retatrutide now?
No. The clinic does not prescribe or sell retatrutide while it remains investigational and lacks verified Pakistani registration and authorized supply.
Does the 28.3% result mean I would lose that amount?
No. It is a group average from one phase 3 trial reported by the manufacturer. Individual response and risk vary, and regulatory review is still required.
When will retatrutide be available in Pakistan?
No responsible date can be promised. Availability would require regulatory decisions, authorized product supply and appropriate prescribing guidance.
Primary sources
- Retatrutide for Obesity—Phase 2 Trial, published June 2023.
- ClinicalTrials.gov: TRIUMPH-1 (NCT05929066), record updated June 2026.
- Lilly TRIUMPH-1 topline release, 21 May 2026. Manufacturer source; full peer-reviewed publication awaited.
- FDA concerns with unapproved GLP-1 drugs, including retatrutide, accessed July 2026.
This analysis is educational and will be updated as evidence and regulatory decisions change. It is not an invitation to obtain or use investigational retatrutide.